Photos accompanying this announcement are available at: ...

The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of noncancerous tumors on ...

The Food and Drug Administration approved mirdametinib, brand name Gomekli, from SpringWorks Therapeutics (SWTX), a kinase inhibitor, for adult ...

The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare ...

SpringWorks Therapeutics (SWTX) announced that the U.S. FDA has approved Gomekli, SpringWorks’ MEK inhibitor, for the treatment of adult and ...

PORTSMOUTH, Va. (WAVY) – In 2010, a group of enthusiastic supporters ran through the cold in Washington, D.C., dropping their pants to raise money for research to help end neurofibromatosis (NF), a ...

SpringWorks Therapeutics (NASDAQ:SWTX), which is reportedly in takeover talks with Merck KGaA (OTCPK:MKGAF) (OTCPK:MKKGY), has received FDA approval for the drug mirdametinib for the treatment of ...

Merck said in a brief statement that discussions are "advanced" but noted that "critical conditions have yet to be met" ...

Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...

Germany's Merck KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer.

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Since We Live in Time packs all the emotions, I felt it's only appropriate that I give you a range of new Max movies that reflect everything A24 has to offer – whether that's a coming-of-age story, a ...